Hu B, et al. - Experts conducted a meta-analysis to evaluate if mixed lineage kinase domain-like protein (MLKL) could be a prognostic biomarker for cancer patients. All relevant articles about the predictive value of abnormally expressed MLKL in patients with any type of tumor were analyzed for this study. In cancer patients, results revealed that reduced MLKL expression was significantly related to poor overall survival and event-free survival. A significant association of reduced expression of MLKL with advanced tumor stage, more lymph node metastasis and older age was seen.